ArticleMolecular and cellular biochemistry2025
CAR19-T/NK cell and circular aptamer-drug conjugate (ApDC) combination treatment increases immunotherapy efficacy.
Article in Molecular and cellular biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A new era in CAR-NK cell therapy: from technological innovations to clinical applications.World journal of pediatrics : WJP · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Chimeric antigen receptor (CAR)-based cell therapies have transformed the treatment of haematological malignancies, especially acute lymphoblastic leukaemia (ALL). However, drug resistance limits long-term efficacy. This study aimed to develop a novel combination therapy using aptamer‒drug conjugates and CAR19-T/natural killer (NK) cells to eliminate tumour cells completely and improve the efficacy of CAR-based cell therapies. A novel circular aptamer‒drug conjugate (C-ApDC) targeting protein tyrosine kinase-7 (PTK7) was designed and synthesized, and CD19 CAR-T and CAR-NK cells were constructed. The stability of C-ApDC was analysed by agarose gel electrophoresis, its binding specificity was evaluated by flow cytometry, and its cytotoxicity was measured by a CCK-8 assay. The synergistic effect between C-ApDC and CAR19-T/NK cells was comprehensively assessed through flow cytometry cytotoxicity analysis. To further validate the feasibility of combination therapy, we synthesized a novel C-ApDC-nanobody conjugate and combined it with CAR19-NK/T cells. The stability of the conjugate was analysed by agarose gel electrophoresis, and the cytotoxic effects of the combination regimen on tumour cells were detected by flow cytometry. C-ApDC exhibited greater stability than linear ApDC and specifically bound to and killed PTK7-expressing Nalm6 cells in vitro. C-ApDC significantly enhanced the cytotoxicity of CAR19-T/NK cells to tumour cells. Similarly, the C-ApDC-nanobody conjugate, when used in combination with CAR19-NK/T cells, exhibited high stability. A combination therapy composed of C-ApDC nanobodies and CAR19-T/NK cells was successfully developed. This innovative approach effectively enhances the cytotoxicity of CAR19-T/NK cells against tumour cells, providing a novel therapeutic strategy for tumour treatment and offering a promising solution to overcome CAR-T resistance.
Indexed as
Identifiers
40652441What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.